LY03005 is an exclusive CNS product developed under Luye Pharma’s New Chemical and Therapeutic Entities (NCE/...
Luye Pharma Group announced today that one of its key central nervous system (CNS) products, Rivastigmine Tran...
This regional initiative aims to raise mental health awareness, supporting patients, physicians and health sys...
Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development ...
To bring Mindfront Health’s EBM interdisciplinary diagnosis and treatment services to China
Requiring twice-weekly administration, the product further increases patient compliance and reduces the burden...
TOP